Advertisement
A live web cast of the presentation will be available on the Company's Website atwww.responsebio.com/newsroom_events_calendar_corporate.asp?menu=1&submenu=3and replays will be available for 14 days starting approximately three hoursafter the initial presentation.
Advertisement
About Response Biomedical
Response Biomedical develops, manufactures and markets rapid on-sitediagnostic tests for use with its RAMP(R) Platform for clinical andenvironmental applications. RAMP(R) represents a new paradigm in diagnosticsthat provides high sensitivity and reliable information in minutes. It isideally suited to both point-of-care testing and laboratory use. The RAMP(R)system consists of a Reader and single-use disposable test cartridges, and hasthe potential to be adapted to more than 250 medical and non-medical testscurrently performed in laboratories. RAMP(R) clinical tests are commerciallyavailable for the early detection of heart attack and congestive heartfailure.
In late 2006, the Company formed a strategic alliance with 3M Company tocommercialize rapid infectious disease tests. In the non-clinical market,RAMP(R) Tests are currently provided for the environmental detection of WestNile Virus, and Biodefense applications including the rapid on-site detectionof anthrax, smallpox, ricin and botulinum toxin. Several other productapplications are under development. Response has achieved CE Marking and itsQuality Management System is registered to ISO 13485: 2003 and ISO 9001: 2000.
Response Biomedical is a publicly traded company, listed on the TSX underthe trading symbol "RBM" and quoted on the OTC Bulletin Board under the symbol"RPBIF". For further information, please visit the Company's website atwww.responsebio.com.
CONTACT: Response Biomedical Contacts: Bill Wickson, Manager, InvestorRelations, Response Biomedical Corporation, Tel (604) 456-6073, Email:[email protected]; Brian Korb, Vice President, The Trout Group LLC,Tel: (646) 378-2923, Email: [email protected]
SOURCE Response Biomedical Corp.
